Effects of Repetitive Transendocardial CD34 + Cell Transplantation in Patients With Nonischemic Dilated Cardiomyopathy

• DOI: 10.1161/circresaha.117.312170
• Publication Date: 2018-06-07T09:05:18Z
• Authors: Bojan Vrtovec; Gregor Poglajen; Matjaz Sever; Gregor Zemljic; Sabina Frljak; Andraz Cerar; Marko Cukjati; Martina Jaklic; Peter Cernelc; François Haddad; Joseph C. Wu
• Keywords: Dilated Cardiomyopathy; Group B; Brain natriuretic peptide

Preclinical data in heart failure models suggest that repetitive stem cell therapy may be superior to single-dose administration.We investigated whether administration of CD34+ cells is patients with nonischemic dilated cardiomyopathy.Of 66 cardiomyopathy, New York Heart Association functional class III, and left ventricular ejection fraction (LVEF) <40% enrolled the study, 60 were randomly allocated (group A, n=30) or single-cell B, n=30). Patients received G-CSF (granulocyte colony-stimulating factor) for 5 days, 80 million collected by apheresis injected transendocardially. In group was repeated at 6 months. All followed 1 year, primary end point difference change LVEF between groups. At baseline, groups did not differ age, sex, LVEF, NT-proBNP (N-terminal pro-B-type natriuretic peptide), 6-minute walk test distance. When directly comparing A B there no significant (from 32.2±9.3% 41.2±6.5% from 30.0±7.0% 37.9±5.3% P=0.40). From baseline months, both improved (+6.9±3.3% P=0.001 +7.1±3.5% P=0.001), (-578±211 pg/mL, P=0.02 -633±305 P=0.01), (+87±21 m, P=0.03 +92±25 P=0.02). contrast, we observed changes months year (LVEF: +2.1±2.3% P=0.19 +0.8±3.1% P=0.56; NT-proBNP: -215±125 P=0.26 -33±205 P=0.77; test: +27±11 P=0.2 +12±18 P=0.42).In does seem associated improvements NT-proBNP, when compared therapy.URL: http://www.clinicaltrials.gov. Unique identifier: NCT02248532.